Zhu et al. [49] recognized that osteonectin (SPARC) restrain the phosphorylation of AKT/mTOR, via the overexpression of miR-29a, thus controlling cancer cell proliferation in hepatocellular carcinoma (HCC). Here, SPARC is linked to hepatocellular carcinoma.